Immunotherapy for Diffuse Large B-cell Lymphoma (DLBCL) in Taiwan, Thailand, and India
Client Success Story
Research Background :
A pharmaceutical company wanted to understand the experience of highly experienced HCPs treating and managing patients with Diffuse Large B-cell Lymphoma (DLBCL). Understanding the current management of DLBCL and current perceptions of CAR T therapy was crucial to the study. To overcome all kinds of concerns, it was important to ascertain the future support and needs expected from the pharmaceutical companies by the HCPs for themselves and R/R DLBCL patients.
How Cultural traits made a difference?
With our experience healthcare recruiters across Asia we were able to recruit specialized Hematology-Oncologists, Hematologists, Medical Oncologists to take a part in web assisted qualitative interviews for this study. We were able to bring reliable and thought-provoking insights as a contribution making it certain for the clients to prevail over the challenges faced by the patients suffering DLBCL. The study was a complete success as the client gained an accurate and deep understanding with respect to the management of DLBCL and unmet needs of HCPs in treating DLBCL and perception around CAR T therapy.
Methodology :
One hour in depth interviews
Markets:
Thailand, Taiwan, and India